Lv1
60 积分 2024-10-20 加入
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
6个月前
已完结
Neoadjuvant chemotherapy plus camrelizumab for locally advanced cervical cancer (NACI study): a multicentre, single-arm, phase 2 trial
6个月前
已完结
The global, regional, and national burden of cancer, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023
6个月前
已关闭
Neoadjuvant PD-1/PD-L1 Inhibitors for Resectable Head and Neck Cancer
8个月前
已完结
Consolidation ALK Tyrosine Kinase Inhibitors versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK+ Non-Small Cell Lung Cancer
9个月前
已完结
Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial
10个月前
已完结
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
10个月前
已完结
Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer
10个月前
已完结
Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV
10个月前
已关闭
Advances in antibody-drug conjugates for endometrial cancer
10个月前
已完结
皖公网安备34019202002308
